Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome

BACKGROUND: Carfilzomib is an irreversible second-generation proteasome inhibitor that has a short elimination half-life but much longer pharmacodynamic (PD) effect based on its irreversible mechanism of action, making it amenable to longer dosing intervals. A mechanistic pharmacokinetic/pharmacodyn...

Descripción completa

Detalles Bibliográficos
Autores principales: Yago, Marc R., Mehta, Khamir, Bose, Maitreyee, Bhagwat, Sharvari, Chopra, Vivek S., Dutta, Sandeep, Upreti, Vijay V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182103/
https://www.ncbi.nlm.nih.gov/pubmed/37072559
http://dx.doi.org/10.1007/s40262-023-01242-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182103/
https://www.ncbi.nlm.nih.gov/pubmed/37072559
http://dx.doi.org/10.1007/s40262-023-01242-6

Ejemplares similares